1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Biotechnology
CPBIO Holding Company Limited

CPBIO Holding Company Limited

7.78
HKD
-0.12
(-1.52%)
2.08BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.49
0.43
0.34
0.29
0.37
0.41
0.37
0.56
0.63
0.69
1.21
2.12
- -
Basic EPS, GAAP
0.08
0.03
0.03
0.06
0.08
0.06
0.06
0.08
-0.03
0.01
0.04
0.13
- -
Free Cash Flow per Basic Share
0.05
0.02
0.06
-0.04
0.01
-0.1
-0.04
-0.11
-0.04
-0.11
-0.01
0.11
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.61
0.61
0.61
0.72
0.77
0.82
0.94
1.05
0.95
0.94
0.97
1.15
1.22
Tangible Book Value per Share
0.58
0.58
0.58
0.68
0.74
0.79
0.92
1.02
0.93
0.92
0.95
1.13
1.19
Basic Weighted Avg Shares
241
236
253
253
253
253
253
253
253
253
253
253
247
Sales/Revenue/Turnover
117
102
87
74
93
105
94
142
159
174
308
536
- -
Operating Margin (%)
6.94
10.01
8.63
1.81
4.19
4.8
2.94
4.37
3.71
-1.95
4.23
7.59
- -
Depreciation Expense
5
5
6
5
5
5
5
8
7
6
8
9
- -
Net Income, GAAP
19
8
8
16
21
16
16
20
-7
3
11
32
- -
Effective Tax Rate (%)
15.19
22.4
18.82
7.14
6.49
9.27
6.06
14.78
- -
35.92
13.3
16.57
- -
Profit Margin (%)
16.59
8.04
9.23
21.95
22.67
15.04
17.37
13.74
-4.19
1.47
3.63
5.98
- -
Working Capital
26
33
51
59
69
60
53
65
52
55
54
87
97
LT Debt
2
1
- -
3
10
7
9
16
12
20
12
9
10
Total Equity
168
168
169
197
210
222
251
284
256
252
261
308
326
Return on Invested Capital (%)
- -
4.27
3.36
0.52
1.66
1.98
1.05
7.02
- -
-0.67
3.62
9.58
- -
Return on Capital (%)
- -
2.92
3.05
7.89
8.94
5.91
5.69
4.35
- -
1.41
3.13
8.34
- -
Return on Common Equity (%)
- -
5.54
5.47
10.22
11.85
8.26
7.66
8.18
-2.77
1.12
4.85
12.59
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
39
- -
65
LT Borrowings
9
- -
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
- -
1
Shares Outstanding
241
241
241
Market Capitalization
224
206
266

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
224
- -
258
Cash, Cash Equivalents & STI
40
- -
37
Accounts Receivable, Net
130
- -
155
Inventories
33
- -
38
Total Current Liabilities
138
- -
161
Payables & Accruals
- -
- -
- -
ST Debt
39
- -
65
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.57%
4.69%
18.18%
Free Cash Flow
-207.78%
-195.98%
-1,195.97%
Net Income, GAAP
38.08%
54.49%
187.03%
Sales/Revenue/Turnover
22.23%
44.86%
74.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
308
2025
- -
- -
- -
- -
536
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.13
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chawalit Na Muangtoun
Full Time Employees
900
Sector
Health technology
Industry
Biotechnology
Address
Far East Finance Centre Hong Kong Hong Kong
IPO Date
Jul 3, 2015
Website
ctei.com.hk
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Chia Tai Enterprises International Limited (3839.HK) manufactures and sells animal health products and chlortetracycline (CTC) primarily in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. The company operates through two main segments: Biochemical, which produces and markets CTC premix, CTC hydrochloride under the Shihao and Citifac brands as feed additives to promote livestock growth, prevent or cure animal diseases, and enhance feed efficiency, as well as other veterinary products including vaccines, test kits, and additives; and Industrial, which trades Caterpillar machinery equipment such as excavators, power generators, bulldozers, and compactors including sales, leasing, and servicing through 50% interests in one of China's four Caterpillar dealers, alongside the manufacture and sale of motorcycle carburetors and automotive parts via joint ventures and associates. It serves farms, pharmaceutical companies, trading firms, and feed mills in the agricultural products and services industry. Founded on October 16, 1987 and headquartered at 21/F, Far East Finance Centre, 16 Harcourt Road, Central, Hong Kong, the company employs approximately 900 people and generates revenue mainly from CTC products and animal health offerings. Recent developments include expanded trading of new animal health products such as vaccines, test kits, and additives with the HOEL Group since August 2023 in response to the latter's animal feed and farming business growth, leading to proposed revised annual caps for purchases under the 2023 Master HOEL Purchase Agreement effective from January 2024 and further expansions into 2025 and 2026; strategic broadening of its veterinary product portfolio through manufacturing and trading; and a partnership with U Power and ICBC Thai to advance intelligent, battery-swapping compatible agricultural drones in Thailand.